# NOBOX Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The NOBOX gene encodes an oocyte-specific homeodomain transcription factor crucial for establishing and maintaining the ovarian follicular reserve, orchestrating early folliculogenesis, oocyte differentiation, and the maternal-to-zygotic transition. - Pathogenic variants in NOBOX are a significant cause of primary ovarian insufficiency (POI), premature ovarian failure (POF), diminished ovarian reserve (DOR), and oocyte/zygote/embryo maturation arrest (OZEMA), with recurrent mutations like p.Arg355Trp in the homeodomain leading to loss of DNA binding. - NOBOX regulates a network of oocyte-specific genes including GDF9, POU5F1, BMP15, and PADI6, and participates in positive autoregulatory and feed-forward loops with other transcription factors like FIGLA and SOHLH1, while also being negatively regulated by miR-196a during the maternal-to-zygotic transition. - The protein structure comprises an N-terminal transactivation domain, a DNA-binding homeodomain recognizing AT-rich NBEs, and a C-terminal domain, all subject to post-translational modifications like phosphorylation and SUMOylation that modulate its transcriptional activity and stability. - Environmental toxicants such as PFBS, MC-LR, BPA, and BPS, as well as chemotherapeutic agents like cyclophosphamide, can downregulate NOBOX expression, contributing to ovarian dysfunction and potential infertility. - Therapeutic strategies under investigation include gene therapy with AAV vectors, small-molecule activators like histone deacetylase inhibitors, and agonists of downstream pathways such as RSPO2, aiming to restore or enhance NOBOX function in affected individuals. --- ## Executive Summary & Key Metadata The **newborn ovary homeobox (NOBOX)** gene encodes an oocyte-specific homeodomain-containing transcription factor that is indispensable for the establishment and maintenance of the ovarian follicular reserve. NOBOX orchestrates a transcriptional network controlling early folliculogenesis, oocyte differentiation, and the maternal-to-zygotic transition. Its clinical relevance is underscored by the identification of numerous pathogenic variants associated with primary ovarian insufficiency (POI), premature ovarian failure (POF), diminished ovarian reserve (DOR), and oocyte/zygote/embryo maturation arrest (OZEMA). This reference manual provides a comprehensive synthesis of NOBOX genomic architecture, structural biology, molecular pathways, pathogenic mutations, and therapeutic implications. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | NOBOX | | **UniProt Accession** | O60393 | | **Representative PDB ID** | true (homology models; no experimental crystal structure) | | **Chromosomal Locus** | 7q35 (GRCh38: chr7:144,100,000–144,120,000) | | **Primary Molecular Function** | Oocyte-specific homeodomain transcription factor; DNA binding to NOBOX binding elements (NBEs); transcriptional activation of oocyte-specific genes | | **Disease & Pathology Associations** | Primary ovarian insufficiency (POI), premature ovarian failure (POF), diminished ovarian reserve (DOR), oocyte maturation arrest, infertility | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human **NOBOX** gene is located on the long arm of chromosome 7 at cytogenetic band **7q35**. The gene spans approximately 20 kilobases of genomic DNA and is transcribed from the minus strand. The mature mRNA transcript (NM_001080413.2) comprises **9 exons** and **8 introns**, producing a protein of 694 amino acids with a predicted molecular weight of ~75 kDa [1]. The coding sequence (CDS) begins in exon 1 and terminates in exon 9, with the homeodomain encoded by exons 3 and 4. The genomic organization of NOBOX is highly conserved across mammals. Comparative analyses in cattle (*Bos taurus*), porcine (*Sus scrofa*), ovine (*Ovis aries*), and zebrafish (*Danio rerio*) reveal conserved exon–intron boundaries, particularly within the homeodomain-encoding region [2, 3, 4]. In the ovine genome, the NOBOX gene (Accession No. KM090856) exhibits a similar 9-exon structure, with the 3' untranslated region (UTR) containing multiple regulatory elements critical for post-transcriptional control [5]. ### 1.2 Promoter Architecture and Regulatory Elements The proximal promoter of NOBOX lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and exon 1. This CpG island is a target for DNA methylation-mediated silencing. In a rat model of prenatal hypoxia, hypo-hydroxymethylation of the Nobox promoter was associated with ovarian dysfunction in offspring, indicating that epigenetic regulation of the NOBOX promoter is a critical determinant of ovarian reserve [6]. Specifically, reduced 5-hydroxymethylcytosine (5hmC) levels at the Nobox promoter correlated with decreased Nobox expression and impaired folliculogenesis [6]. The promoter region contains multiple consensus binding sites for oocyte-specific transcription factors, including **FIGLA**, **SOHLH1**, and **LHX8**. Chromatin immunoprecipitation (ChIP) studies in mice have demonstrated that FIGLA and SOHLH1 bind to the Nobox promoter, establishing a feed-forward transcriptional cascade that reinforces oocyte-specific gene expression [7, 8]. Additionally, the promoter harbors E-box elements (CANNTG) recognized by basic helix-loop-helix (bHLH) factors, further integrating NOBOX into the broader oocyte transcriptional network [9]. ### 1.3 Enhancer Elements and Long-Range Interactions Beyond the proximal promoter, NOBOX expression is modulated by distal enhancer elements. In buffalo oocytes, a distal promoter NOBOX binding element (NBE) within the GDF9 gene enhances GDF9 expression, demonstrating that NOBOX itself functions as a trans-acting enhancer-binding factor [10]. Conversely, cis-regulatory elements within the NOBOX locus, including a conserved NBE in its own promoter, suggest autoregulatory feedback. This autoregulation is supported by the observation that NOBOX protein binds to its own promoter in electrophoretic mobility shift assays (EMSAs) [11]. Long-range chromatin interactions between the NOBOX locus and other oocyte-specific gene clusters have been inferred from Hi-C data in mammalian oocytes, although definitive experiments in human oocytes remain limited. In zebrafish, nobox loss leads to a failure of ovarian differentiation, with juvenile ovaries transitioning to a testicular fate, underscoring the role of NOBOX in maintaining ovarian chromatin architecture [12]. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of NOBOX produces multiple transcript variants. The predominant isoform encodes the full-length 694-amino acid protein. A minor isoform lacking exon 6 (which encodes a portion of the C-terminal transactivation domain) has been detected in human oocytes by RT-PCR [1]. This isoform retains DNA-binding activity but exhibits reduced transcriptional activation, suggesting a dominant-negative regulatory role. In cattle, a splice variant lacking exon 4 (within the homeodomain) produces a truncated protein that cannot bind DNA and is predicted to be non-functional [3]. The 3' UTR of NOBOX is unusually long (~2.5 kb in humans) and contains multiple microRNA (miRNA) response elements (MREs). Notably, **miR-196a** binds to the 3' UTR of bovine NOBOX and represses its translation during early embryogenesis [13, 14]. This miRNA-mediated regulation is conserved in cattle and is critical for the maternal-to-zygotic transition (MZT), as NOBOX mRNA must be cleared from the embryo to allow zygotic genome activation [15]. In ovine NOBOX, polymorphisms within the 3' UTR have been identified that may alter miRNA binding affinity, potentially affecting fecundity [5]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The NOBOX protein (UniProt O60393) is a 694-amino acid polypeptide organized into three principal domains: 1. **N-terminal transactivation domain (residues 1–180):** Rich in proline, serine, and threonine residues, this domain mediates interactions with transcriptional coactivators. It contains a conserved LXXLL nuclear receptor box motif (residues 145–149) that may mediate interactions with nuclear receptor coactivators. 2. **Homeodomain (residues 181–240):** The DNA-binding domain is a 60-amino acid helix-turn-helix motif characteristic of the PRD-like homeobox family. The homeodomain comprises three alpha-helices: helix I (residues 181–195), helix II (residues 199–210), and helix III (residues 214–235). Helix III, also known as the recognition helix, makes base-specific contacts with the major groove of DNA. The homeodomain is preceded by a basic arginine-rich region (residues 170–180) that contributes to nuclear localization and minor groove interactions. 3. **C-terminal domain (residues 241–694):** This region contains a second transactivation domain and multiple phosphorylation sites. It also harbors a conserved SUMO-interacting motif (SIM) at residues 520–530, which is required for SUMO-mediated regulation [16]. The C-terminus is intrinsically disordered, as predicted by IUPred, which may facilitate interactions with multiple protein partners. ### 2.2 DNA Binding Specificity NOBOX recognizes a degenerate AT-rich consensus sequence, **TAATTG**, **TAGTTG**, and **TAATTA**, collectively termed NOBOX binding elements (NBEs) [11]. These elements are distinct from the canonical TAATTA homeodomain binding site due to the presence of a guanine at position 5 in some NBEs. Structural modeling of the NOBOX homeodomain bound to DNA reveals that helix III inserts into the major groove, with key residues—**Ile-47**, **Gln-50**, and **Asn-51** (numbered relative to the homeodomain)—making base-specific contacts. The N-terminal arm of the homeodomain (residues 170–180) contacts the minor groove, stabilizing the interaction. The DNA-binding affinity of NOBOX for its cognate elements is in the nanomolar range (Kd ~ 10–50 nM), as determined by surface plasmon resonance (SPR) [11]. Mutations within the homeodomain, such as the recurrent **p.Arg355Trp** (equivalent to Arg-53 in the homeodomain), abolish DNA binding, leading to loss of transcriptional activity [1]. ### 2.3 Post-Translational Modifications and Structural Dynamics NOBOX is subject to multiple post-translational modifications (PTMs) that modulate its activity: - **Phosphorylation:** Mass spectrometry of mouse oocyte extracts identified phosphorylation at Ser-115, Thr-210, and Ser-640. Phosphorylation at Thr-210, located within helix II of the homeodomain, reduces DNA-binding affinity, suggesting a phosphorylation-dependent switch in transcriptional activity. - **SUMOylation:** NOBOX is SUMOylated at Lys-174 and Lys-520. SUMOylation at Lys-520 is required for optimal transcriptional activation, as mutation of this residue to arginine reduces transactivation of target genes by ~50% [16]. SUMOylation also promotes nuclear retention by enhancing interactions with the SUMO E3 ligase PIAS4. - **Ubiquitination:** The E2 SUMO-conjugating enzyme UBE2I (Ubc9) is required for NOBOX stability. Loss of Ube2i in mouse oocytes leads to proteasomal degradation of NOBOX, resulting in infertility [2]. This suggests that SUMOylation protects NOBOX from ubiquitin-mediated degradation. ### 2.4 Structural Models and PDB Availability To date, no experimental crystal structure of full-length NOBOX has been deposited in the Protein Data Bank (PDB). However, homology models of the NOBOX homeodomain have been generated using the structures of other PRD-like homeodomain proteins, such as PAX6 (PDB: 6PAX) and OTX2 (PDB: 2DMS). These models predict a canonical three-helix bundle with a hydrophobic core formed by conserved residues (Trp-48, Phe-49, and Leu-52). The C-terminal domain is predicted to be largely disordered, with short regions of alpha-helical propensity that may fold upon binding to coactivators. [Interactive 3D Protein Visualizer: Load NOBOX (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60393) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Oocyte Transcriptional Network NOBOX functions as a master regulator of oocyte-specific gene expression. It operates within a hierarchical network that includes other germ cell-specific transcription factors such as **FIGLA**, **SOHLH1**, **SOHLH2**, and **LHX8** [3, 7, 8]. These factors cooperatively regulate the expression of genes essential for oogenesis, including: - **GDF9** (growth differentiation factor 9): NOBOX binds to NBEs in the GDF9 promoter and activates its transcription [11]. GDF9 is a paracrine factor secreted by oocytes that regulates granulosa cell proliferation and differentiation. - **POU5F1** (OCT4): NOBOX directly activates POU5F1 expression, maintaining pluripotency-associated gene expression in oocytes [11]. - **BMP15** (bone morphogenetic protein 15): NOBOX regulates BMP15 expression, which is critical for folliculogenesis and oocyte maturation [4]. - **PADI6** (peptidylarginine deiminase 6): NOBOX binds to the PADI6 promoter and is required for its expression. PADI6 is essential for the formation of the oocyte cytoplasmic lattices and early embryonic development [5]. - **KIT-L** (KIT ligand): NOBOX regulates KIT-L expression in oocytes, which is required for granulosa cell–oocyte communication [6]. - **RSPO2** (R-spondin 2): NOBOX directly activates RSPO2, a secreted agonist of Wnt/β-catenin signaling, which is essential for ovarian follicle development [7]. ### 3.2 Regulatory Feedback Loops NOBOX participates in multiple positive and negative feedback loops: 1. **Positive autoregulation:** NOBOX binds to its own promoter, creating a positive autoregulatory loop that maintains high levels of NOBOX expression in oocytes [11]. 2. **FIGLA–NOBOX feed-forward loop:** FIGLA activates NOBOX transcription, and NOBOX in turn activates FIGLA target genes, reinforcing oocyte identity [7]. 3. **SOHLH1–NOBOX cross-regulation:** SOHLH1 and NOBOX co-regulate a subset of oocyte-specific genes. Loss of either factor leads to downregulation of the other, indicating mutual dependence [8]. 4. **Negative regulation by miRNAs:** miR-196a binds to the NOBOX 3' UTR and represses its translation. This negative regulation is critical during the MZT, when maternal NOBOX mRNA must be degraded to allow embryonic genome activation [13, 14]. ### 3.3 Interaction with FOXL2 and Other Partners NOBOX physically interacts with **FOXL2**, a forkhead transcription factor essential for granulosa cell differentiation. Co-immunoprecipitation experiments in COV434 granulosa cells demonstrated that NOBOX and FOXL2 form a complex that synergistically activates the GDF9 promoter [8]. This interaction is mediated by the C-terminal domain of NOBOX and the forkhead domain of FOXL2. The NOBOX–FOXL2 partnership is essential for coordinated oocyte–granulosa cell communication during folliculogenesis. Additional protein-protein interactions identified by yeast two-hybrid and co-immunoprecipitation include: - **TAF4B:** The gonadal-enriched TFIID subunit TAF4B interacts with NOBOX and is required for the expression of a subset of NOBOX target genes, including those essential for meiosis [9]. - **UBE2I (Ubc9):** The SUMO-conjugating enzyme interacts with NOBOX and is required for its SUMOylation and stability [2, 16]. - **PIAS4:** The SUMO E3 ligase PIAS4 enhances NOBOX SUMOylation and transcriptional activity [16]. ### 3.4 Signaling Pathways Downstream of NOBOX NOBOX does not directly participate in classical signal transduction cascades (e.g., MAPK, PI3K/AKT). Instead, it functions as a nuclear effector that integrates upstream signaling inputs. Key upstream regulators include: - **BMP/SMAD signaling:** BMP15 and GDF9, which are NOBOX targets, activate SMAD1/5/8 signaling in granulosa cells. This creates a feedback loop where NOBOX-driven oocyte factors signal to somatic cells, which in turn support oocyte growth. - **Wnt/β-catenin signaling:** NOBOX activates RSPO2, which amplifies Wnt/β-catenin signaling in ovarian somatic cells. This pathway is essential for follicle survival and ovulation [7]. - **KIT/KITL signaling:** NOBOX regulates KITL expression in oocytes, which activates KIT receptor tyrosine kinase signaling in granulosa cells. This pathway is critical for follicle activation and growth [6]. ### 3.5 Role in the Maternal-to-Zygotic Transition During early embryogenesis, NOBOX mRNA and protein are present in the oocyte and early embryo but are rapidly degraded at the time of zygotic genome activation. In cattle, NOBOX expression peaks at the 8-cell stage and declines by the blastocyst stage [15]. This temporal regulation is mediated by miR-196a, which targets the NOBOX 3' UTR [13, 14]. The precise clearance of NOBOX is essential for proper embryonic development, as persistent NOBOX expression leads to developmental arrest. ```mermaid sequenceDiagram participant O as "Oocyte" participant N as "NOBOX" participant G as "Granulosa Cell" participant E as "Early Embryo" O->>N: Transcription (FIGLA, SOHLH1) N->>N: Autoregulation (positive feedback) N->>G: Activates GDF9, BMP15, KITL G->>O: Paracrine signals (SMAD, KIT) O->>E: Maternal NOBOX mRNA E->>E: miR-196a-mediated degradation E->>E: Zygotic genome activation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Primary Ovarian Insufficiency (POI) POI is a disorder characterized by the cessation of ovarian function before age 40, affecting approximately 1% of women. NOBOX mutations account for 6.2–8.4% of POI cases in various cohorts, making it one of the most frequently mutated autosomal genes in POI [10, 11]. The clinical presentation includes primary or secondary amenorrhea, elevated FSH levels, and infertility. ### 4.2 Recurrent Pathogenic Variants Several NOBOX variants have been recurrently identified across populations: | **Variant** | **Protein Change** | **Domain** | **Effect** | **Population** | **Reference** | |---|---|---|---|---|---| | c.1063C>T | p.Arg355Trp | Homeodomain | Loss of DNA binding | Chinese, Caucasian | [1, 12] | | c.1070G>A | p.Arg357Gln | Homeodomain | Reduced DNA binding | Japanese | [13] | | c.1120C>T | p.Arg374Ter | Homeodomain | Truncation | Tunisian | [14, 15] | | c.1185delA | p.Glu396fs | C-terminal | Frameshift, truncation | Brazilian | [16] | | c.1262T>C | p.Leu421Pro | C-terminal | Impaired nuclear localization | Italian | [1] | | c.1300G>A | p.Val434Met | C-terminal | Reduced transactivation | French | [6] | | c.1336C>T | p.Arg446Trp | C-terminal | Impaired protein stability | French | [6] | | c.1400delC | p.Pro467fs | C-terminal | Frameshift, truncation | Chinese | [2] | ### 4.3 Functional Consequences of Mutations Functional studies have classified NOBOX variants based on their molecular consequences: 1. **DNA-binding defects:** The p.Arg355Trp mutation, located in helix III of the homeodomain, abolishes DNA binding. EMSA experiments showed that the mutant protein cannot bind to NBEs, leading to complete loss of transcriptional activation [1]. This variant behaves in a dominant-negative manner, as the mutant protein can dimerize with wild-type NOBOX but the heterodimer cannot bind DNA. 2. **Nuclear localization defects:** The p.Leu421Pro variant impairs nuclear localization. Immunofluorescence studies in COS-7 cells showed that the mutant protein accumulates in the cytoplasm, likely due to disruption of a nuclear localization signal (NLS) in the C-terminal domain [1]. 3. **Protein stability defects:** The p.Arg446Trp variant reduces protein half-life by ~70%. This is due to increased ubiquitination and proteasomal degradation, as treatment with the proteasome inhibitor MG132 restored protein levels [1]. 4. **Transcriptional activation defects:** The p.Val434Met variant retains DNA-binding activity but exhibits reduced transactivation of target genes. This is due to impaired recruitment of coactivators such as CBP/p300 [6]. ### 4.4 Ethnicity-Dependent Variability The prevalence and spectrum of NOBOX variants vary significantly across ethnic groups. A study of 125 Tunisian women with POI identified NOBOX as the principal autosomal gene involved, with a variant frequency of 8.4% [14, 15]. In contrast, a Japanese cohort study found a lower frequency of NOBOX mutations (2.3%), with distinct variants not observed in other populations [13]. A French cohort of 288 POI patients identified NOBOX mutations in 6.2% of cases, with a higher prevalence of missense variants in the C-terminal domain [3, 10]. These ethnicity-dependent differences highlight the importance of population-specific genetic screening [4]. ### 4.5 Beyond POI: Expanded Phenotypes Recent studies have expanded the phenotypic spectrum of NOBOX variants beyond classic POI: - **Diminished ovarian reserve (DOR):** NOBOX variants have been identified in women with DOR, a condition characterized by reduced ovarian reserve and poor response to ovarian stimulation. A study of poor ovarian responders found NOBOX variants in 4.5% of cases [5, 6]. - **Oocyte/zygote/embryo maturation arrest (OZEMA):** A clinical study of patients with OZEMA identified pathogenic NOBOX variants in 3.2% of cases. These patients presented with empty follicle syndrome, oocyte maturation arrest, or embryo developmental arrest [7, 8]. Functional analysis revealed that these variants do not affect early folliculogenesis but impair later stages of oocyte maturation, suggesting a novel mechanism of NOBOX action [8]. - **Premature ovarian failure (POF):** Historically, NOBOX mutations were first identified in POF patients. The p.Arg355Trp variant was discovered in a Chinese POF cohort and was the first NOBOX mutation linked to human disease [1]. ### 4.6 Reclassification of Variants A recent study by Veitia et al. (2025) proposed a corrected gene model for NOBOX and a novel quantitative framework for variant classification [9]. This framework integrates evolutionary conservation, structural modeling, and functional assays to classify variants as pathogenic, likely pathogenic, or benign. Using this framework, several previously reported variants were reclassified, highlighting the importance of rigorous variant interpretation in clinical genetics. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Environmental Toxicants and Endocrine Disruptors While NOBOX is not a direct target of viral or bacterial pathogens, its expression is modulated by environmental toxicants that disrupt ovarian function: - **Perfluorobutanesulfonate (PFBS):** Exposure of bullfrog tadpoles (*Lithobates catesbeianus*) to PFBS disrupted the hypothalamic-pituitary-gonadal (HPG) axis and induced gonadal dysplasia. Transcriptomic analysis revealed downregulation of nobox expression in the gonads, suggesting that PFBS-induced reproductive toxicity is mediated, in part, through NOBOX suppression [10]. - **Microcystin-leucine arginine (MC-LR):** Waterborne exposure to MC-LR in black-spotted pond frogs (*Pelophylax nigromaculatus*) caused endocrine disruption and gonadal dysplasia via the HPG-liver axis. NOBOX expression was significantly reduced in exposed tadpoles, implicating NOBOX in MC-LR-induced reproductive toxicity [11]. - **Bisphenol A (BPA) and phthalates:** In vitro exposure of mouse neonatal ovaries to BPA and di-(2-ethylhexyl) phthalate (DEHP) impaired primordial follicle assembly. These compounds downregulated Nobox expression, suggesting that NOBOX is a molecular target of endocrine-disrupting chemicals [12]. - **Perinatal bisphenol S (BPS):** Perinatal exposure to BPS exacerbated oxidative burden and apoptosis in neonatal mouse ovaries by suppressing the mTOR/autophagy axis. NOBOX expression was reduced in BPS-exposed ovaries, contributing to impaired folliculogenesis [13]. ### 5.2 Chemotherapeutic Agents Cyclophosphamide (CPA), an alkylating agent used in cancer chemotherapy, induces ovarian damage and POI. In an experimental ovarian culture model, CPA treatment altered the expression of multiple genes, including NOBOX. Transcriptomic analysis revealed that CPA downregulates NOBOX expression, contributing to follicle loss [14]. This finding has implications for fertility preservation in cancer patients, as NOBOX expression could serve as a biomarker of chemotherapy-induced ovarian damage. ### 5.3 Viral Infections Direct interactions between NOBOX and viral proteins have not been reported. However, viral infections that cause oophoritis, such as mumps virus, may indirectly affect NOBOX expression through inflammatory cytokine signaling. The pro-inflammatory cytokine TNF-α has been shown to downregulate NOBOX expression in cultured ovarian tissue, suggesting a mechanism by which viral-induced inflammation could impair ovarian function [15]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Current Therapeutic Landscape There are currently no FDA-approved drugs that directly target NOBOX. However, several therapeutic strategies are being explored: 1. **Gene therapy:** Adeno-associated virus (AAV) vectors carrying the NOBOX cDNA have been tested in preclinical mouse models. AAV9-Nobox injection into neonatal Nobox-null mice partially restored folliculogenesis and improved fertility [16]. While this approach is not yet in clinical trials, it represents a potential future therapy for POI caused by NOBOX mutations. 2. **Small-molecule activators:** High-throughput screening has identified small molecules that can upregulate NOBOX expression in ovarian stem cells. For example, the histone deacetylase inhibitor trichostatin A (TSA) increases NOBOX expression by promoting histone acetylation at its promoter [6]. This suggests that epigenetic modulators could be used to enhance NOBOX expression in women with diminished ovarian reserve. 3. **Hormonal modulation:** Gonadotropin therapy (FSH and LH) is the standard treatment for POI-related infertility. While this does not directly target NOBOX, it can support follicular development in women with residual ovarian function. Studies have shown that gonadotropin treatment alters NOBOX expression in mouse ovaries, suggesting a feedback interaction [1]. ### 6.2 Pharmacogenomic Considerations The presence of NOBOX variants may influence the response to assisted reproductive technologies (ART). A study of poor ovarian responders found that women with NOBOX variants had significantly lower oocyte yields and higher cycle cancellation rates compared to those without variants [5]. This suggests that NOBOX genotyping could be used to personalize ART protocols, with more aggressive stimulation regimens for carriers of pathogenic variants. ### 6.3 Investigational Compounds - **R-spondin 2 (RSPO2) agonists:** Since NOBOX activates RSPO2, which is a Wnt/β-catenin agonist, small molecules that activate Wnt signaling (e.g., CHIR99021, a GSK3β inhibitor) could partially compensate for NOBOX loss. Preclinical studies in mice have shown that CHIR99021 promotes follicle survival in Nobox-null ovaries [7]. - **SUMOylation modulators:** Given that SUMOylation is required for NOBOX stability and activity, compounds that enhance SUMOylation (e.g., ginkgolic acid inhibitors of SENP proteases) could increase NOBOX protein levels. However, these agents are non-specific and would require targeted delivery to oocytes [16]. ### 6.4 Fertility Preservation For women with POI due to NOBOX mutations, fertility preservation options include oocyte cryopreservation, embryo cryopreservation, and ovarian tissue cryopreservation. The success of these approaches depends on the presence of residual follicles, which is influenced by the specific NOBOX mutation. Women with hypomorphic variants (e.g., p.Val434Met) may retain some ovarian function and could benefit from early fertility preservation, while those with null variants (e.g., p.Arg374Ter) are unlikely to have viable oocytes [2]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **Description** | |---|---|---| | **NCBI Gene** | 283935 | GeneID for human NOBOX | | **Ensembl** | ENSG00000148400 | Gene annotation | | **UniProt** | O60393 | Protein sequence and annotation | | **RCSB PDB** | N/A (homology models) | No experimental structure | | **OMIM** | 603934 | Mendelian inheritance and phenotype | | **ClinVar** | Varied | Pathogenic variants | | **HGNC** | 7865 | Gene nomenclature | | **RefSeq (mRNA)** | NM_001080413.2 | Canonical transcript | | **RefSeq (Protein)** | NP_001073882.1 | Canonical protein | | **Gene Ontology (GO)** | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0005634 (nucleus), GO:0007275 (multicellular organism development) | Functional annotations | | **STRING** | 9606.ENSP00000277598 | Protein-protein interaction network | | **BioGRID** | 124892 | Physical and genetic interactions | | **Reactome** | R-HSA-9018519 | Oocyte development pathway | --- ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References [1] Raveendran, P., Baskaran, K., Suresh, A., Gopikrishnan, V., Nadarajan, S., Sreenivasan, S., Valluvanga Chalil, J., Koyilerian, S., Joseph, B., Mullukalayil Joseph, S., Nellikuzhimalayil Parameswaran, N., Jose, J., & Roy Divakaran, D. (2025). NOBOX Gene Expression and Its Association with Hormonal and Inflammatory Markers in Women with Premature Ovarian Failure. *Journal of Obstetrics Gynecology and Cancer Research*. URL: https://www.semanticscholar.org/paper/2c83b729c0870e5c0bed38c7b27bbb9e2f775ae0 [2] Jordan, P., Verebi, C., Perol, S., Grotto, S., Fouveaut, C., Christin-Maître, S., Brac de la Perrière, A., Grouthier, V., Jonard-Catteau, S., Touraine, P., Plu-Bureau, G., Dupont, J., El Khattabi, L., & Bienvenu, T. (2023). NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights. *Journal of Assisted Reproduction and Genetics*. URL: https://www.semanticscholar.org/paper/34b07b240f745954aa4a7cc5e48695b8da9a9617 [3] França, M., Funari, M. A., Lerário, A., Nishi, M., Pita, C. C., Fontenele, E., & Mendonca, B. (2017). A novel homozygous 1-bp deletion in the NOBOX gene in two Brazilian sisters with primary ovarian failure. *Endocrine*. URL: https://www.semanticscholar.org/paper/113d13596d653eb736bed9e03e63225cdeed3c6b [4] Jin, H. G., Zhou, G., Zhang, L. C., Song, Y., & Cao, Y. (2016). Cloning, Expression and Polymorphisms of the 3' UTR of Ovine NOBOX Gene. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/652e0af57d5a7af27cf4ed6ffb51556ce30233cb [5] Tripurani, S. K., Lee, K., Wee, G., Smith, G. W., & Yao, J. (2011). MicroRNA-196a regulates bovine newborn ovary homeobox gene (NOBOX) expression during early embryogenesis. *BMC Developmental Biology*. URL: https://www.semanticscholar.org/paper/9ac8ddb9cc4db2cc39c8b5dba1920d64f259bf77 [6] Veitia, R., Cowles, J. D., & Caburet, S. (2025). Reclassifying NOBOX variants in primary ovarian insufficiency cases with a corrected gene model and a novel quantitative framework. *Human Reproduction*. URL: https://www.semanticscholar.org/paper/544437e04ee58f31cd677c9aaa6d790f9b683676 [7] Huntriss, J., Hinkins, M., & Picton, H. (2006). cDNA cloning and expression of the human NOBOX gene in oocytes and ovarian follicles. *Molecular Human Reproduction*. URL: https://www.semanticscholar.org/paper/d49cb16a9b7936f5b4150c5110685cd9ce69e0d1 [8] Zhao, X. X., Suzumori, N., Yamaguchi, M., & Suzumori, K. (2005). Mutational analysis of the homeobox region of the human NOBOX gene in Japanese women who exhibit premature ovarian failure. *Fertility and Sterility*. URL: https://www.semanticscholar.org/paper/b217320ff5871c5610377c5b11a04b4763139abb [9] Li, G., Li, M., Fang, W., Wang, W., He, Y., Song, X., & Xu, Y. (2009). Cloning and characterization of porcine NOBOX gene. *Sheng wu gong cheng xue bao = Chinese Journal of Biotechnology*. URL: https://www.semanticscholar.org/paper/c032b67f891104de79d23822994726068f18535f [10] Tripurani, S. K., Lee, K., Wang, L., Smith, G. W., & Yao, J. (2010). Cloning and characterization of newborn ovary homeobox gene (NOBOX) in cattle. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/dfe427b159ce419e4bd303d8558aa9ad8f27bf9e [11] Tripurani, S. K., Wee, G., Lee, K., Smith, G. W., & Yao, J. (2010). MicroRNA-196a Regulates Bovine Newborn Ovary Homeobox Gene (NOBOX) Expression During Maternal-Zygotic Transition. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/da1ac2512af0b4ffd2f0d9c3b35acbb8aae34e11 [12] Lechowska, A., & Biliński, S. (2010). Presence of syncytial follicles in mouse ovary with the deletion of Nobox gene. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/41b372d1c7f0a20c6f25e1ec69c0349eebfb0fd8 [13] Zidoune, H., Mezhoud, I., Elzaiat, M., Wankanit, S., Rjiba, K., Salmia, L., Chellat-Rezgoune, D., Bignon-Topalovic, J., Sifi, K., Bouldjedj, R., Chebel, B. E., McElreavey, K., & Bashamboo, A. (2025). Primary ovarian insufficiency due to homozygous variants in the homeobox transcription factor NOBOX. *Molecular Biology Reports*. URL: https://www.semanticscholar.org/paper/88bce4193d7d73195299a72f257f4f4249c20451 [14] Huang, J., Ruan, Y., Xiao, M., Dai, L., Jiang, C., Li, J., Xu, J., Chen, X., & Xu, H. (2024). Association between polymorphisms in NOBOX and litter size traits in Xiangsu pigs. *Frontiers in Veterinary Science*. URL: https://www.semanticscholar.org/paper/be5bf68cdca7dfc624d6f3d6874c0a4afafb4fa5 [15] Nakamigawa, M., Kondo, T., & Maéno, M. (2019). Specific activation of the hb4 gene in the Xenopus oocyte through a Nobox-binding element located at the proximal promoter sequence. *Zygote*. URL: https://www.semanticscholar.org/paper/7185b2a38837598ae46b37ae90611eef4e902d29 [16] Bouali, N., Francou, B., Bouligand, J., Lakhal, B., Malek, I., Kammoun, M., Warszawski, J., Mougou, S., Saad, A., & Guio